Washington D.c., DC5 Active Studies

Prostate Cancer Clinical Trials in Washington D.c., DC

Find 5 actively recruiting prostate cancer clinical trials in Washington D.c., DC. Connect with local research sites and explore new treatment options.

5
Active Trials
3
Sponsors
1,358
Enrolling

Recruiting Prostate Cancer Studies in Washington D.c.

RecruitingWashington D.c., DCNCT05803941

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 17...

700 participants
Novartis Pharmaceuticals
View Study Details
RecruitingWashington D.c., DCNCT04787744

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-...

464 participants
VA Office of Research and Development
View Study Details
RecruitingWashington D.c., DCNCT04038502

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant p...

100 participants
VA Office of Research and Development
View Study Details
RecruitingWashington D.c., DCNCT06798558

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will...

54 participants
Hackensack Meridian Health
View Study Details
RecruitingWashington D.c., DCNCT04104893

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either ...

40 participants
VA Office of Research and Development
View Study Details

About Prostate Cancer Clinical Trials in Washington D.c.

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 5 prostate cancer clinical trials recruiting participants in Washington D.c., DC. These studies are seeking a combined 1,358 participants. Research is being sponsored by Novartis Pharmaceuticals, VA Office of Research and Development, Hackensack Meridian Health. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Washington D.c. — FAQ

Are there prostate cancer clinical trials in Washington D.c.?

Yes, there are 5 prostate cancer clinical trials currently recruiting in Washington D.c., DC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Washington D.c.?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Washington D.c. research site will contact you about next steps.

Are clinical trials in Washington D.c. free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Washington D.c. studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 5 active trials in Washington D.c. are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated March 2, 2026 from ClinicalTrials.gov